Compare Johnson & Johnson (JNJ) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs JPMorgan Chase & Co — how do they compare? Johnson & Johnson trades at $251.25 (market cap $598.96B), while JPMorgan Chase & Co trades at $343.38 (market cap $900.78B). The key difference: JPMorgan Chase & Co is the larger of the two by market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | JPM | |
|---|---|---|
Market Cap | $598.96B | $900.78B |
Volume | 6,156,228 | 10,479,943 |
Sector | Health | Financials |
52-Week High | $267.24 | $346.91 |
52-Week Low | $164.36 | $282.84 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
JPMorgan Chase & Co. (JPM) trades at $342.57, up 0.43% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.52 and net income margin of 33.4%, though Q4 2025 EPS missed expectations. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings, with analyst consensus leaning bullish.
JPM offers upside to the $372.73 consensus price target, driven by earnings beats and sector resilience, but faces risks from geopolitical tensions, cybersecurity threats, and volatile cash flows. Investors should weigh solid profitability against macroeconomic headwinds highlighted in recent shareholder communications.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
